Is JCRRF or NOBL a better dividend investment in 2026?

JCRRF currently yields 3.22% with a 5% 5-year dividend growth rate. NOBL yields 4.00% with 5% growth. The better choice depends on your goal: NOBL offers higher current income.

What is the dividend yield difference between JCRRF and NOBL?

JCRRF has a forward dividend yield of 3.22% ($0.13/share annually). NOBL yields 4.00% ($2.00/share annually). The yield gap is 0.78 percentage points.

Home › Compare › JCRRF vs NOBL

JCRRF vs NOBL: Dividend Comparison 2026

JCRRF yields 3.22% · NOBL yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 JCRRF wins by $590.30M in total portfolio value

INVESTMENT

TIME HORIZON10 years

JCRRF

● Live price

3.22%

Share price

$4.17

Annual div

$0.13

5Y div CAGR

100%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$590.33M

Annual income

$557,098,169.44

Full JCRRF calculator →

NOBL

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full NOBL calculator →

Portfolio growth — JCRRF vs NOBL

📍 JCRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	JCRRF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, JCRRF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

JCRRF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCRRF

Annual income on $10K today (after 15% tax)

$273.77/yr

After 10yr DRIP, annual income (after tax)

$473,533,444.02/yr

NOBL

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, JCRRF beats the other by $473,532,679.71/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCRRF + NOBL for your $10,000?

JCRRF: 50%NOBL: 50%

100% NOBL50/50100% JCRRF

Portfolio after 10yr

$295.18M

Annual income

$278,549,534.32/yr

Blended yield

94.37%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCRRF buys

NOBL buys

No recent congressional trades found for JCRRF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricJCRRFNOBL

Forward yield	3.22%	4.00% ✓
Annual dividend / share	$0.13	$2.00 ✓
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	100% ✓	5%
Portfolio after 10y	$590.33M ✓	$28.0K
Annual income after 10y	$557,098,169.44 ✓	$899.19
Total dividends collected	$587.89M ✓	$6.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: JCRRF vs NOBL ($10,000, DRIP)

Year	JCRRF Portfolio	JCRRF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$11,344	$644.17	$11,120	$420.00	+$224.00 → JCRRF
2	$13,504	$1,365.91	$12,357	$458.31	+$1.1K → JCRRF
3	$17,489	$3,039.22	$13,721	$499.76	+$3.8K → JCRRF
4	$26,070	$7,356.96	$15,227	$544.58	+$10.8K → JCRRF
5	$48,393	$20,498.67	$16,885	$593.02	+$31.5K → JCRRF
6	$122,906	$71,124.57	$18,713	$645.34	+$104.2K → JCRRF
7	$469,147	$337,637.75	$20,724	$701.81	+$448.4K → JCRRF
8	$2,910,974	$2,408,986.96	$22,938	$762.73	+$2.89M → JCRRF
9	$31,053,709	$27,938,966.99	$25,372	$828.41	+$31.03M → JCRRF
10	$590,325,638	$557,098,169.44	$28,047	$899.19	+$590.30M → JCRRF

JCRRF vs NOBL: Complete Analysis 2026

JCRRF — Stock

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Full JCRRF Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →

📬

Get this JCRRF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCRRF vs SCHD JCRRF vs JEPI JCRRF vs O JCRRF vs KO JCRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.